?????? ????????????????????????? ?????????????? ?? ????.gene in patients relapsing right after procedure With all the BCL2 antagonist venetoclax. 66 Resistance to those brokers has long been connected to these mutations in around 70% of scenarios, Whilst they tend to be subclonal as well as their distinct purpose leading to resistance must be confi